litlas
Log inCreate account

David A. Cooper

Active 1977–2024

173
Papers
37,753
Citations
106
h-index
171
i10-index

Citations

Citations per year for David A. Cooper1978: 2 citations1979: 2 citations1980: 2 citations1983: 3 citations1984: 1 citations1985: 6 citations1986: 7 citations1987: 5 citations1988: 2 citations1989: 4 citations1990: 6 citations1991: 19 citations1992: 12 citations1993: 41 citations1994: 38 citations1995: 37 citations1996: 69 citations1997: 114 citations1998: 202 citations1999: 246 citations2000: 352 citations2001: 393 citations2002: 400 citations2003: 420 citations2004: 415 citations2005: 345 citations2006: 299 citations2007: 289 citations2008: 297 citations2009: 373 citations2010: 280 citations2011: 280 citations2012: 215 citations2013: 212 citations2014: 145 citations2015: 134 citations2016: 162 citations2017: 119 citations2018: 105 citations2019: 493 citations2020: 463 citations2021: 429 citations2022: 378 citations2023: 284 citations2024: 347 citations2025: 183 citations2026: 22 citations1981–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,348 citing papers, 31.4% of this breakdownUnited Kingdom: 781 citing papers, 7.3% of this breakdownAustralia: 556 citing papers, 5.2% of this breakdownFrance: 501 citing papers, 4.7% of this breakdownCanada: 449 citing papers, 4.2% of this breakdownGermany: 439 citing papers, 4.1% of this breakdownItaly: 391 citing papers, 3.7% of this breakdownChina: 367 citing papers, 3.4% of this breakdownSpain: 327 citing papers, 3.1% of this breakdownNetherlands: 323 citing papers, 3% of this breakdownSwitzerland: 295 citing papers, 2.8% of this breakdownSouth Africa: 214 citing papers, 2% of this breakdown
0%31.4%Other 25.1%

Institutions

Fields

  • Medicine50.9%
  • Immunology and Microbiology24.8%
  • Computer Science13.8%
  • Biochemistry, Genetics and Molecular Biology4.1%
  • Environmental Science1.8%
  • Engineering1%
  • Other3.6%

Topics

  • HIV Research and Treatment14.1%
  • HIV/AIDS drug development and treatment10.5%
  • HIV/AIDS Research and Interventions10.4%
  • HIV-related health complications and treatments7.6%
  • Immune Cell Function and Interaction3%
  • Cryptography and Data Security2.4%
  • Other52%

Coauthors

All papers

Open in search
  1. Status report on the third round of the NIST Post-Quantum Cryptography Standardization process

    Authors: Gorjan Alagic, Daniel Apon, David A. Cooper, Quynh Dang, Thinh Dang, John Kelsey, Jacob Lichtinger, Yi-Kai Liu, Carl A. Miller, Dustin Moody, René Peralta, Ray Perlner, Angela Robinson, Daniel Smith-Tone - National Institute of Standards and Technology 2022 cited by 365

  2. Status report on the first round of the NIST post-quantum cryptography standardization process

    Authors: Gorjan Alagic, Jacob Alperin-Sheriff, Daniel Apon, David A. Cooper, Quynh Dang, Yi-Kai Liu, Carl A. Miller, Dustin Moody, René Peralta, Ray Perlner, Angela Robinson, Daniel Smith-Tone - National Institute of Standards and Technology 2019 cited by 355

  3. Status report on the second round of the NIST post-quantum cryptography standardization process

    Authors: Dustin Moody, Gorjan Alagic, Daniel Apon, David A. Cooper, Quynh H Dang, John Kelsey, Yi-Kai Liu, Carl A. Miller, René Peralta, Ray A Perlner, Angela Robinson, Daniel Smith-Tone, Jacob Alperin-Sheriff - National Institute of Standards and Technology 2020 cited by 291

  4. Recommendation for Stateful Hash-Based Signature Schemes

    Authors: David A. Cooper, Daniel Apon, Quynh Dang, Michael Davidson, Morris J. Dworkin, Carl A. Miller - National Institute of Standards and Technology 2020 cited by 89

  5. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study

    Authors: Benjamin R. Bavinton, Angie N. Pinto, Nittaya Phanuphak, Beatriz Grinsztejn, Garrett P Prestage, Iryna Zablotska, Fengyi Jin, Christopher K. Fairley, Richard D. Moore, Norman Roth, Mark Bloch, Catherine Pell, Anna McNulty, David Baker, Jennifer Hoy, Ban Kiem Tee, David J. Templeton, David A. Cooper, Sean Emery, Anthony D. Kelleher, Andrew E. Grulich, Andrew E. Grulich, Iryna Zablotska, Garrett P Prestage, Fengyi Jin, Benjamin R. Bavinton, Beatriz Grinsztejn, Nittaya Phanuphak, David A. Cooper, Anthony D. Kelleher, Sean Emery, Christopher K. Fairley, David P. Wilson, Kersten K. Koelsch, Kathy Triffitt, Nicolas Doong, David Baker, Mark Bloch, David J. Templeton, Anna McNulty, Catherine Pell, Jennifer Hoy, Ban Kiem Tee, Richard D. Moore, Norman Roth, David N. Orth, Angie N. Pinto - The Lancet HIV 2018 cited by 519

  6. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

    Authors: Andrew E. Grulich, Rebecca Guy, Janaki Amin, Fengyi Jin, Christine Selvey, Jo Holden, H Schmidt, Iryna Zablotska, Karen Price, Bill Whittaker, Kerry Chant, Craig Cooper, Scott McGill, Barbara Telfer, Barbara Yeung, Gesalit Levitt, Erin Ogilvie, Nila J. Dharan, Mohamed Hammoud, Stefanie Vaccher, Lucy Watchirs-Smith, Anna McNulty, David J. Smith, Debra Allen, David Baker, Mark Bloch, Rohan I. Bopage, Katherine Brown, Andrew Carr, Christopher Carmody, Kym L Collins, Robert Finlayson, Rosalind Foster, Eva Jackson, David A. Lewis, Josephine Lusk, Catherine OʼConnor, Nathan Ryder, Emanuel Vlahakis, Phillip Read, David A. Cooper, Don Smith, Catriona Ooi, Sarah Martin, Tuck Meng Soo, David J. Templeton, David H. Townson, Brad Forssman, Nick Doong, Gai Han Thai, Ben Anderson, Hugh MacLeod, Nicolas Parkhill - The Lancet HIV 2018 cited by 369

  7. HIV-1 DNA predicts disease progression and post-treatment virological control

    Authors: James P. Williams, Jacob Hurst, Wolfgang Stöhr, Nicola Robinson, Helen Brown, Martin Fisher, Sabine Kinloch, David A. Cooper, Mauro Schechter, Giuseppe Tambussi, Sarah Fidler, Mary Carrington, Abdel Babiker, Jonathan Weber, Kersten K. Koelsch, Anthony D. Kelleher, Rodney E. Phillips, John Frater, on behalf of the SPARTAC trial investigators - eLife 2014 cited by 307

  8. Characterization of CD4+ CTLs Ex Vivo

    Authors: Victor Appay, John Zaunders, Laura Papagno, Julian Sutton, Angel Jaramillo, Anele Waters, Philippa Easterbrook, Pat Grey, Don Smith, Andrew J. McMichael, David A. Cooper, Sarah Rowland‐Jones, Anthony D. Kelleher - The Journal of Immunology 2002 cited by 540

  9. Quantum resistant public key cryptography: a survey

    Authors: Ray A. Perlner, David A. Cooper - Symposium on Identity and Trust on the Internet, IDtrust 2009 cited by 137

  10. High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40)

    Authors: John Zaunders, C. Mee Ling Munier, Nabila Seddiki, Sarah Pett, Susanna Ip, Michelle Bailey, Yin Xu, Kai Brown, Wayne B. Dyer, Min Kim, Robert De Rose, Stephen J. Kent, Lele Jiang, Samuel N. Breit, Sean Emery, Anthony L. Cunningham, David A. Cooper, Anthony D. Kelleher - The Journal of Immunology 2009 cited by 180

  11. Guidelines for the selection, configuration, and use of Transport Layer Security (TLS) implementations

    Authors: Kerry A. McKay, David A. Cooper - National Institute of Standards and Technology 2019 cited by 52

  12. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

    Authors: Andrew Carr, Katherine Samaras, Samantha Burton, Matthew Law, Judith Freund, Donald J. Chisholm, David A. Cooper - AIDS 1998 cited by 2,403

  13. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

    Authors: Ronald T. Mitsuyasu, Thomas C. Merigan, Andrew Carr, Jerome A. Zack, Mark A. Winters, Cassy Workman, Mark Bloch, Jacob Lalezari, S. Hegewisch Becker, Lorna Thornton, Bisher Akil, Homayoon Khanlou, Robert Finlayson, Robert McFarlane, Don Smith, Roger Garsia, Dávid Ma, Matthew Law, John M. Murray, Christof von Kalle, Julie A. Ely, Sharon M Patino, Alison E. Knop, Philip Wong, Alison V. Todd, Margaret Haughton, C.J. Fuery, Janet L. Macpherson, Geoff Symonds, Louise Evans, Susan M. Pond, David A. Cooper - Nature Medicine 2009 cited by 263

  14. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

    Authors: Jacob Hurst, Matthias Hoffmann, Matthew Pace, James P. Williams, John Thornhill, Elizabeth Hamlyn, Jodi Meyerowitz, Chris Willberg, Kersten K. Koelsch, Nicola Robinson, Helen Brown, Martin Fisher, Sabine Kinloch, David A. Cooper, Mauro Schechter, Giuseppe Tambussi, Sarah Fidler, Abdel Babiker, Jonathan Weber, Anthony D. Kelleher, Rodney E. Phillips, John Frater - Nature Communications 2015 cited by 178

  15. Recommendation for Stateful Hash-Based Signature Schemes

    Authors: David A. Cooper - 2019 cited by 24

  16. Relation between HIV viral load and infectiousness: a model-based analysis

    Authors: David P. Wilson, Matthew Law, Andrew E. Grulich, David A. Cooper, John Kaldor - The Lancet 2008 cited by 366

  17. Predictors of disease progression in HIV infection: a review

    Authors: Simone E Langford, Jintanat Ananworanich, David A. Cooper - AIDS Research and Therapy 2007 cited by 332

  18. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

    Authors: Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew Grimm, David A. Cooper, Sharon R. Lewin, Ole S. Søgaard, Thomas A. Rasmussen, Stephen J. Kent, Anthony D. Kelleher, Miles P. Davenport - PLoS Pathogens 2015 cited by 119

  19. Adverse effects of antiretroviral therapy

    Authors: Andrew Carr, David A. Cooper - The Lancet 2000 cited by 1,065

  20. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

    Authors: Mark Nelson, Christine Katlama, Joan Montaner, David A. Cooper, Brian Gazzard, Bonaventura Clotet, Adriano Lazzarin, Knud Schewe, Joep M. A. Lange, Christina Wyatt, Sue Curtis, Shan-Shan Chen, Stephen A. Smith, Norbert Bischofberger, James F. Rooney - AIDS 2007 cited by 352

  21. Specific antibody‐dependent cellular cytotoxicity responses associated with slow progression of HIV infection

    Authors: Leia Wren, Amy W. Chung, Gamze Isitman, Anthony D. Kelleher, Matthew S. Parsons, Janaki Amin, David A. Cooper, Ivan Stratov, Marjon Navis, Stephen J. Kent - Immunology 2012 cited by 144

  22. Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging

    Authors: Edwin Leeansyah, Paul Cameron, Ajantha Solomon, Surekha Tennakoon, Pushparaj Velayudham, Maëlenn Gouillou, Tim Spelman, Anna C. Hearps, Christopher K. Fairley, De Villiers Smit, Anna Pierce, Jude Armishaw, Suzanne M. Crowe, David A. Cooper, Kersten K. Koelsch, Junping Liu, John Chuah, Sharon R. Lewin - The Journal of Infectious Diseases 2013 cited by 137

  23. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

    Authors: Andrew Carr, Katherine Samaras, Donald J. Chisholm, David A. Cooper - The Lancet 1998 cited by 1,093

  24. Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria

    Authors: Katherine Samaras, Handan Wand, Matthew Law, Sean Emery, David A. Cooper, Andrew Carr - Diabetes Care 2006 cited by 322